[{"id":"47bf8c34-12d0-4fbd-900e-a934d4279c7a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01154816","created_at":"2021-01-18T04:35:50.917Z","updated_at":"2024-07-02T16:36:45.053Z","phase":"Phase 2","brief_title":"Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia","source_id_and_acronym":"NCT01154816","lead_sponsor":"Children's Oncology Group","biomarkers":" SMARCD3","pipe":"","alterations":" ","tags":["SMARCD3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 118","initiation":"Initiation: 02/01/2011","start_date":" 02/01/2011","primary_txt":" Primary completion: 12/31/2015","primary_completion_date":" 12/31/2015","study_txt":" Completion: 06/30/2019","study_completion_date":" 06/30/2019","last_update_posted":"2020-05-13"}]